Sun Pharma completes tender offer for InSite Vision
Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of Press Release dated October 28, 2015 titled "Sun Pharma completes tender offer for InSite Vision".28-10-2015
28-10-2015
Sun Pharma to announce second quarter results on November 07, 2015
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated October 26, 2015, titled "Sun Pharma to announce second quarter results on November 07, 2015".26-10-2015
Q2 results on Nov 07, 2015
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 07, 2015, interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2015 (Q2).Further note that, window closure for trading by designated persons as per Insider Trading Rules of the Company will be from October 29, 2015 to November 10, 2015 (both days inclusive).23-10-2015
Sun Pharma Settles Patent Litigation with Acorda Therapeutics
Sun Pharma has settled a patent litigation with US-based Acorda Therapeutics Inc over Ampyra extended-release tablets, which is used in the treatment of multiple sclerosis patients.21-10-2015
Updates
Sun Pharmaceutical Industries Ltd has informed BSE that the Company, along with its subsidiary (Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics. Inc. to resolve the pending patent litigation involving Ampyra (dalfampridine) Extended-Release Tablets in the US. The pending patent litigation was filed by Acorda Therapeutics in the U.S. District Court for the District of Delaware in response to Sun Pharma's submission of...21-10-2015
Shareholding Pattern for September 30, 2015
Sun Pharmaceutical Industries Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015.21-10-2015
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant S Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE14-10-2015
Sun Pharma withdraws suit filed by Ranbaxy against US FDA
Sun Pharma says it do not believe that the withdrawal of said lawsuit will have any materially adverse financial impact on the company09-10-2015
Withdrawal of lawsuit filed against US FDA by erstwhile Ranbaxy
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has withdrawn its appeal in the lawsuit filed by erstwhile Ranbaxy Laboratories Limited (Ranbaxy) in November 2014 in a U.S. District Court against U.S. Food and Drug Administration (FDA). This lawsuit challenged FDA's revocation of Ranbaxy's tentative approvals for its generic versions of Nexium and Valcyte in the US. The Company do not believe that the withdrawal of said lawsuit...09-10-2015
AGM on Oct 31, 2015
Sun Pharmaceutical Industries Ltd has informed BSE that the 23rd Annual General Meeting (AGM) of the Company will be held on October 31, 2015.06-10-2015